EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?

Sarah Allegra iD, Francesco Chiara, Daniela Di Grazia iD, Marco Gaspari iD, Silvia De Francia

Pharmaceuticals · 24.05.2023 · 16 (6) · 786

DOI: 10.3390/ph16060786 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 24.05.2023. Verfasst von Sarah Allegra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Until the last quarter of the 20th century, sex was not recognized as a variable in health research, nor was it believed to be a factor that could affect health and illness. Researchers preferred studying male models for a variety of reasons, such as simplicity, lower costs, hormone confounding effects, and fear of liability from perinatal exposure in case of pregnancy. Equitable representation is imperative for determining the safety, effectiveness, and tolerance of therapeutic agents for all consumers. Decades of female models’ underrepresentation in preclinical studies has resulted in inequality in the understanding, diagnosis, and treatment of disease between the sexes. Sex bias has been highlighted as one of the contributing factors to the poor translation and replicability of preclinical research. There have been multiple calls for action, and the inclusion of sex as a biological variable is increasingly supported. However, although there has been substantial progress in the efforts to include more female models in preclinical studies, disparities today remain. In the present review, we consider the current standard practice of the preclinical research setting, why the sex bias exists, why there is the need to include female models, and what risks may arise from continuing this exclusion from experimental design.

Schlagwörter

Stichwörter der Autor:innen

pharmacologypreclinical experimentationsex differences

Autor:innen und Institutionen

  • Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Orbassano, Italy.

ORCID-Profile: Sarah Allegra, Daniela Di Grazia, Marco Gaspari

Zitieren

APA

Allegra, S., Chiara, F., Di Grazia, D., Gaspari, M., & De Francia, S. (2023). Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?. Pharmaceuticals, 16(6), 786. https://doi.org/10.3390/ph16060786

Vancouver

Allegra S, Chiara F, Di Grazia D, Gaspari M, De Francia S. Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?. Pharmaceuticals. 2023;16(6):786. doi:10.3390/ph16060786

BibTeX
@article{Allegra2023,
  author = {Allegra, Sarah and Chiara, Francesco and Di Grazia, Daniela and Gaspari, Marco and De Francia, Silvia},
  title = {Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {6},
  pages = {786},
  doi = {10.3390/ph16060786}
}
Kostenlos starten →